Vesatolimod (GS-9620) is safe and pharmacodynamically active in HIV-infected individuals

• S. Riddler,
• M. Para,
• C. Benson,
• A. Mills,
• M. Ramgopal,
• E. Dejesus,
• C. Brinson,
• J. Cyktor,
• J. Mellors,
• S. Guo,
• B. Doehle,
• S. Markova,
• H. Patel,
• H. Graham,
• J. Hesselgesser,
• R. Geleziunas,
• D. Brainard,
• S. McCallister,
• D. Sengupta

Affiliations

S. Riddler

University of Pittsburgh School of Medicine, Infectious Diseases Division, Pittsburgh, PA, USA

M. Para

Ohio State University, Wexner Medical Center, Columbus, OH, USA

C. Benson

University of California San Diego, UCSD Antiviral Research Center, San Diego, CA, USA

A. Mills

SoCal Men's Medical Group, Los Angeles, CA, USA

M. Ramgopal

Midway Immunology and Research Center, LLC, Fort Pierce, FL, USA

E. Dejesus

Orlando Immunology Center, Orlando, FL, USA

C. Brinson

Central Texas Clinical Research, Austin, TX, USA

J. Cyktor

University of Pittsburgh, Department of Medicine, Pittsburgh, PA, USA

J. Mellors

University of Pittsburgh, Department of Medicine, Pittsburgh, PA, USA

S. Guo

Gilead Sciences, Foster City, CA, USA

B. Doehle

Gilead Sciences, Seattle, WA, USA

S. Markova

Gilead Sciences, Foster City, CA, USA

H. Patel

Gilead Sciences, Foster City, CA, USA

H. Graham

Gilead Sciences, Foster City, CA, USA

J. Hesselgesser

Gilead Sciences, Foster City, CA, USA

R. Geleziunas

Gilead Sciences, Foster City, CA, USA

D. Brainard

Gilead Sciences, Foster City, CA, USA

S. McCallister

Gilead Sciences, Foster City, CA, USA

D. Sengupta

Gilead Sciences, Foster City, CA, USA